Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RaySearch Laboratories AB ( ($SE:RAY.B) ) has issued an announcement.
RaySearch Laboratories AB has announced that the Greater Poland Cancer Center (WCO) has expanded its use of the RayStation treatment planning system to include advanced proton therapy. This expansion will allow WCO to integrate photon and proton workflows into a unified system, enhancing efficiency and enabling personalized cancer treatments. The move underscores RaySearch’s leadership in proton treatment planning and its flexibility across multiple radiotherapy techniques, potentially strengthening its market position and offering significant benefits to WCO’s patient care capabilities.
The most recent analyst rating on ($SE:RAY.B) stock is a Buy with a SEK255.00 price target. To see the full list of analyst forecasts on RaySearch Laboratories AB stock, see the SE:RAY.B Stock Forecast page.
More about RaySearch Laboratories AB
RaySearch Laboratories AB is a medical technology company that develops innovative software solutions for improved cancer treatment. The company markets the RayStation treatment planning system and the oncology information system RayCare. RaySearch’s software has been sold to over 1,100 clinics in 47 countries, and it was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm. The company’s shares have been listed on Nasdaq Stockholm since 2003.
Average Trading Volume: 142,921
Technical Sentiment Signal: Buy
Current Market Cap: SEK7.7B
For an in-depth examination of RAY.B stock, go to TipRanks’ Overview page.